期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

伏立康唑引起他克莫司血药浓度升高2例 被引量：7

下载PDF
导出
摘要 1病例介绍 1．1病例 1患者男，45y，因慢性肾功能不全尿毒症期于2010—06—25日行同种异体肾移植术，术后移植肾功能恢复良好，术后予他克莫司、吗替麦考酚酸酯、强的松治疗，1w前受凉后出现低热，最高至37．8℃，胸片示：
作者 冯光军 张庆
机构地区 湖北省丹江口市第一医院药学部 南方医科大学南方医院药学部
出处 《今日药学》 CAS 2011年第2期128-130,共3页 Pharmacy Today
关键词 伏立康唑 他克莫司 血药浓度
分类号 R969.2 [医药卫生—药理学]
  • 相关文献

参考文献8

  • 1申兰慧,石涛,张岩,张胜强.新一代广谱抗真菌药伏立康唑[J].东南大学学报（医学版）,2004,23(1):62-67. 被引量：21
  • 2Capone D,Tarantino G,Polichetti G,et al.Absence ofpharmacokinetic interference of moxifloxacin on cyclospo-rine and tacrolimus in kidney transplant recipients. JClin Pharmacol . 2010
  • 3Matsuda H,Iwasaki K,Shiraga T,et al.Interactions ofFK506 (tacrolimus)with clinically important drugs. Research Communications in Molecular Pathology and Pharmacology . 1996
  • 4Hui-Hua Chang,Nan-Yao Lee,Wen-Chien Ko,et al.Voriconazole inhibition of tacrolimus metabolism in a kid-ney transplant recipient with fluconazole-resistant crypto-coccal meningitis. International Journal of InfectiousDiseases . 2010
  • 5Capone D,Tarantino G,Gentile Ae,t al.Effects of vori-conazole on tacrolimus metabolism in a kidney transplantrecipient. Journal of Clinical Pharmacy and Thera-peutics . 2010
  • 6Kawazoe H,Takiguchi Y,Tanaka H,et al.Change of theBlood Concentration of Tacrolimus after the Switch fromFluconazole to Voriconazole in Patients Receiving Alloge-neic Hematopoietic Stem Cell Transplantation. Biological and Pharmaceutical Bulletin . 2006
  • 7Felipe CR,Park SI,Pinheiro-Machado PG,et al.Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. Fundamental and Clinical Pharmacology . 2009
  • 8Raman Venkataramanan,Shimin Zang,Timothy Gayowski,et al.Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes. Antimicrobial Agents and Chemotherapy . 2002

二级参考文献27

  • 1CHANDRASEKAR P H,MANAVATHU E,VORICONAZOLE A.Second-generation trizole[J].Drugs Today,2001,37(2):135-148.
  • 2YUET W.Voriconazole versus amphotericin for primary therapy of invasive aspergillosis[J].N Engl J Med,2002,347(6):408-415.
  • 3HOFFMAN H L,RATHBURN R C.Review of the safety and efficacy of voriconazole[J].Expert Opin Investig Drugs,2002,11():409-429.
  • 4POTOSKI B A,BROWN J.The safety of voriconazole[J].Clin Infect Dis,2002,35(10):1273-1275.
  • 5ULLMANN A J.Review of the safety,tolerability,and drug interactions of the new antifungal agents caspofungin and voriconazole[J].Curr Med Res Opin,2003,19(4):263-271.
  • 6GUPTA A K,TOMAS E.New antifungal agents[J].Dermatol Clin,2003,21(3):565-76.
  • 7FLOREA N R,KUTI J L,QUINTILIANE R.Voriconazole:a novel azole antifungal[J].Formulary,2002,37:1-10.
  • 8SABO J A,ABDEL-RAHMAN S M.Voriconazole:a new triazole antifungal[J].Ann Pharmacother,2000,34(9):1032-1043.
  • 9JEU L,PIACENTI F J,LYAKHOVETSKIY A G,et al.Voriconazole[J].Clin Ther,2003,25(5):1321-381.
  • 10CHANDRASEKAR P H,MANAVATHU E.Voriconazole:a second-generation triazole[J].Drugs Today (Barc),2001,37(2):135-148.

共引文献20

同被引文献86

引证文献7

二级引证文献25

今日药学
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部